What does a “glipizide cyclohexyl isocyanate” patent mean?
“Glipizide cyclohexyl isocyanate” usually refers to a chemical form or intermediate involving glipizide and cyclohexyl isocyanate. Patents covering such terms typically aim to protect one or more of the following: a specific compound form, a synthetic step, a salt/derivative, or an improved manufacturing method that uses cyclohexyl isocyanate in the process. Without the specific patent document number or assignee, the exact scope (drug product vs. intermediate vs. process claim) can’t be confirmed.
What patents might cover glipizide itself versus glipizide derivatives?
A search for “glipizide” patents generally pulls up several generations of intellectual property, including:
- Active-drug composition claims (formulations, tablets, controlled release).
- Chemical-entity claims for specific derivatives or salt forms.
- Process claims for producing glipizide or specific intermediates used in synthesis.
- Use claims (where and how the compound is used).
A “cyclohexyl isocyanate” term points more toward chemistry and manufacturing (intermediates/derivatives/process) than toward glipizide’s basic therapeutic use.
How do you find the exact patent you mean?
To identify “the” patent, you typically need at least one of:
- Patent number (US/EP/WO, etc.)
- Publication number (e.g., “WO…”, “US…A1”)
- Assignee/company name
- Inventor names
- A direct quote from the claim or the abstract
- The jurisdiction (US vs. EP vs. WO)
With only the phrase “glipizide cyclohexyl isocyanate,” multiple unrelated patents could match parts of the chemistry text.
How long does a glipizide-related patent protection last?
In general terms, pharmaceutical patents are often 20 years from the earliest effective filing date, but the enforceable life can be extended or changed by exclusivity rules, adjustments, or regulatory protections that depend on the country. For drug products, specific term extensions/exclusivities may apply. The exact expiration date for a “glipizide cyclohexyl isocyanate” patent depends on the earliest priority date and the relevant jurisdiction.
What happens if you’re asking about infringement or “can a generic launch”?
Whether another company can launch depends on what the protected claims cover:
- If claims cover an intermediate or manufacturing process step that generics must use, process-based infringement risk is possible.
- If claims cover a particular salt/derivative or formulation, generics using a different form or method may avoid infringement but still must meet bioequivalence/approval requirements.
- If claims are narrow (specific examples only), design-around is more feasible than for broad chemical coverage.
To answer this accurately, the exact patent claims (and the generic’s formulation/process) must be compared.
What I need from you to give a precise answer
Share any one of the following and I can tell you which patent it is, what it claims, and the practical implications:
- The patent number/publication number
- Link to the patent document
- The assignee or applicant
- The exact wording you saw (claim/abstract text)
If you paste the claim excerpt that includes “cyclohexyl isocyanate,” I can also help interpret what part of the chemistry the patent is trying to protect.